KOSDAQ large cap
HLB
A biotech advancing development of the targeted anticancer drug rivoceranib. KOSDAQ large-cap constituent. Baseline node ahead of value-chain research; promoted to a full node once AI question demand is observed.
028300.KQ Updated Jul 11, 2026 2 AI consumers· 1 recurring
Annual return · 2026-07-10'21-29.6%'22+3.3%'23+134.2%'24+18.6%'25-31%YTD-34.1%
Money in ▸·
HLB
▸ Money out·
Financials & Segments
- Segments · Drug development (rivoceranib) · Medical devices and other
Revenue from
No refined links yet.
Pays to
No refined links yet.